Compare Regeneron Pharmaceuticals Inc (REGN) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Raymond James Financial, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B), while Raymond James Financial, Inc. trades at $158.14 (market cap $30.51B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.5× Raymond James Financial, Inc.'s market cap, and Raymond James Financial, Inc. pays the higher dividend (1.36%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Raymond James Financial, Inc. for 74 Days on average.
| REGN | RJF | |
|---|---|---|
Market Cap | $76.14B | $30.51B |
Volume | 500,239 | 1,206,253 |
Sector | Health | Financials |
52-Week High | $852.03 | $181.18 |
52-Week Low | $557.73 | $140.89 |
Typical Hold Time | 107 Days | 74 Days |
Enterprise Value | $70.85B | $24.37B |
Dividend Yield | 0.51% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Raymond James Financial (RJF) trades at $157.29, down 1.4% with a bearish technical signal. The company shows strong fundamentals with consistent earnings beats, 15.4% net margin, and 18.5% ROE. Recent Q3 2026 results featured record revenues of $3.93 billion, beating estimates. Analysts maintain a Hold consensus with $184 price target, representing 17% upside potential from current levels.
RJF presents a mixed outlook with strong operational performance offset by technical weakness. The stock offers value at 13.7x P/E with dividend growth potential, but faces headwinds from rising expenses and market volatility. Institutional activity shows mixed signals with both position increases and decreases among major holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
